SHOCKWAVE THERAPY

Next most likely to help: Mental health care Best in-office treatment alternative to prescription: Shockwave therapy Best OTC budget options to try: ED rings and/or certain supplements And now, for those in a hurry, here’s a quick snapshot of our specific recommendations across that roadmap.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Phosphodiesterase type 5 (PDE5) inhibitors are the most effective oral drugs in the treatment of ED,9,12 and should be considered first-line therapy.8,14,17 Retail sales of sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra) approached $1.48 billion in 2007.18 Sildenafil has been found to be effective and safe in cases of ED associated with diabetes mellitus17,19 and spinal cord injury,20 and in men with sexual dysfunction secondary to antidepressant therapy.21 Compared with placebo, sildenafil has been shown to improve erections (74 versus 21 percent; number needed to treat [NNT] = 2)22 and results in more frequent intercourse attempts (57 versus 21 percent; NNT = 3).23 Approximately one third of men with ED do not respond to therapy with PDE5 inhibitors. These agents are not effective for improving libido.24 The three PDE5 inhibitors are considered to be relatively similar in effectiveness, but there are differences in dosing, onset of action, and duration of therapeutic effect (Table 6).25 There are no rigorous data to suggest that one PDE5 inhibitor is superior to another. An open-label trial found that patients preferred tadalafil and vardenafil over sildenafil,26 yet most evidence supports equal effectiveness between sildenafil and vardenafil.27 PDE5 inhibitors are generally well tolerated, with mild transient adverse effects of headache, flushing, dyspepsia, rhinitis, and abnormal vision. Headache is the most commonly reported adverse effect, occurring in approximately 10 percent of patients. Rare but important adverse effects include dizziness, syncope, and nonarteritic anterior optic neuropathy (predominantly from crossover phosphodiesterase type 6 inhibition). PDE5 inhibitors should not be taken concomitantly with nitrates because this may lead to a synergistic effect, resulting in a potentially serious, even fatal, decrease in blood pressure. PDE5 inhibitors are metabolized by the cytochrome P450 3A4 and may affect metabolism of protease inhibitors and antifungal medications.

Product	Dosage	Quantity + Bonus	Price
Cialis Generic	40mg	30 + 4 Pills	74.97€ 71.40€
Kamagra 100 mg	100 mg	120 + 6 Pills	330.74€ 314.99€
Cialis Professional	40mg	10 Pills	65.09€ 61.99€
Kamagra Soft Tabs	100 mg	84 + 4 Pills	233.05€ 221.95€
Super Kamagra	160 mg	20 + 4 Pills	155.35€ 147.95€
Viagra Generic	25mg	60 + 4 Pills	71.99€ 68.56€
Cialis Generic	10mg	20 Pills	48.23€ 45.93€
Kamagra Oral Jelly	100mg	110 + 9 Sachets	334.87€ 318.92€
Levitra Generic	60mg	60 + 4 Pills	198.85€ 189.38€
Cialis Super Active	20mg	270 + 30 Pills	661.49€ 629.99€
Viagra Generic	100mg	180 + 8 Pills	199.37€ 189.88€
Cialis Generic	10mg	60 + 6 Pills	105.81€ 100.77€

Intracavernosal pressure and PDE5 activity are androgen-dependent. The prevalence of hypogonadism (defined as a morning serum total testosterone level less than 300 ng per dL [10.41 nmol per L]) in men with ED is estimated to be 5 to 10 percent.13,28 In men with hypogonadism, testosterone supplementation is superior to placebo in improving erections and sexual function. Response rates are higher in primary versus secondary testicular failure, and with transdermal versus oral or intramuscular testosterone.13 Supplementation is also associated with improved satisfaction with erectile function and sexual desire.29 Men with hypogonadism who failed a trial of sildenafil were found to have significant improvement in erectile function with the addition of testosterone supplementation.30 Testosterone supplementation may result in erythrocytosis, elevated serum trans-aminase levels, exacerbation of untreated sleep apnea, benign prostatic hyperplasia, and an increased risk of adenocarcinoma of the prostate. Men receiving testosterone supplementation require more frequent monitoring of hemoglobin, serum transaminase, and prostate-specific antigen levels, and prostate examinations.31 Alprostadil (Caverject) is a viable second-line therapeutic option for the treatment of ED. It should initially be administered in the physician's office at the lowest dose and sequentially titrated to an adequate erectile response while monitoring for syncope. The physicians should also provide education on self-administration.8 Intra-cavernosal alprostadil is more effective, better tolerated, and preferred by men over the intraurethral form.32 Common adverse effects of intraurethral alprostadil include local penile pain, urethral bleeding, dizziness, and dysuria.

Helping Your Partner with Erectile Dysfunction

Men with ED should be considered for cardiovascular risk screening.15 ED rates differ significantly in patients with established coronary artery disease (CAD). On average, ED symptoms present three years earlier than CAD symptoms.37 Men with ED have a 75 percent increased risk of peripheral vascular disease.38 The Prostate Cancer Prevention Trial determined that men with ED have a significantly greater likelihood of having angina, myocardial infarction, stroke, transient ischemic attack, congestive heart failure, or cardiac arrhythmia compared with men without ED.39 Because most men are asymptomatic before an acute coronary syndrome, ED may serve as a sentinel marker for prompting discussions centered on promotion of cardiovascular risk stratification and modification. Erectile dysfunction (ED) is a common condition. One recent study estimated that roughly a third of men struggle with it.1 Though the condition does affect more older men than younger men, its impact spans age groups. Indeed, while half of all ED patients in the U.S.

Horny goat weed

are over the age of 60, one study found that over 25% of men under age 40 suffered from ED to some extent.2 If any of this describes you, then you’re not alone at all. ED is very treatable, and several treatments work for most men, but "most" may technically mean only more than 50% of ED sufferers. The truth is that ED has various underlying causes, and those who are confronting it face varying challenges in treatment due to other potential health conditions. So, the question is: What is best erection pills the best treatment for you? Aside from underlying health considerations, everything from price to how you take a medication can affect your decision.

Are there any natural remedies for erectile dysfunction?

But we're here to demystify ED and your treatment options. To help you out, we’ve reviewed the major online providers and treatments and analyzed a large swath of relevant scientific research. In this guide, we’ll break down all of your best options. First, to orient you to this landscape, here is a roadmap that breaks down the diverse treatment paths you might take and our characterization of their merits. Most likely to help: Prescription PDE5i medication like sildenafil (Viagra), tadalafil (Cialis), etc. Common adverse effects of intracavernosal alprostadil include penile pain, edema and hematoma, lady era tablets palpable nodules or plaques, and priapism. Patients should be informed about the potential for occurrence of prolonged erections and should seek emergent medical evaluation for rigid erections lasting longer than four hours. Priapism is most commonly treated with aspiration of blood from the corpus cavernosum under local anesthetic. If this treatment is insufficient, then intra-cavernosal injections of phenylephrine should be performed with hemodynamic monitoring to watch for severe hypertension, tachycardia, or arrhythmia. Vacuum pump devices are a noninvasive second-line option (Figure 2). They are contraindicated in men with sickle cell anemia or blood dyscrasias, and in those taking anticoagulants.

Erectile Dysfunction Treatment FAQs

If used properly, adverse effects and potential risks are negligible, yet there may be a substantial learning curve. When first- and second-line therapies have failed, surgical implantation of an inflatable penile prosthesis can be considered in consultation with a urologist (Figure 3).

Area of Research	Description	Promising Developments	Challenges
Gene Therapy	Targeting genetic causes of ED	Experimental treatments	Delivery and safety concerns
Stem Cell Therapy	Regenerating erectile tissue	Early clinical trials	Efficacy and long-term effects
NO-Donors and Nitric Oxide Modulators	Enhancing natural nitric oxide production	New drug candidates	Side effects and regulation
Pharmacogenomics	Personalized medicine based on genetics	Custom drug development	Complexity of genetic profiling

Patients should be counseled regarding risks, benefits, and expectations of this procedure. The AUA does not endorse penile venous reconstructive surgery or surgeries to limit venous outflow from the penis. Penile arterial reconstructive surgery is controversial and more rigorous trials are needed to prove short- and long-term effectiveness.16 Korean red ginseng (Panax ginseng) at 900 mg three times daily has been reported to improve erections but not overall sexual experience.33 Yohimbine has shown superiority over placebo for treatment of ED with limited adverse effects,34 but is not recommended by the AUA because of questions about its safety and effectiveness.8 Some dietary supplements marketed for treatment of ED obtainable via the Internet (e.g., Super X, Stamina-Rx) contain PDE5 inhibitors (sildenafil 30 mg and tadalafil 20 mg, respectively). Although these and other similar products claim to be free of any adverse effects, they have the same risks as PDE5 inhibitors.35 When there is no obvious medical etiology for ED, psychosocial factors should be explored. The potential clue that psychosocial lovegra women factors may be a cause is that a man is able to achieve normal erections and orgasm through masturbation or sex with a partner other than the “index case” partner with whom he has erectile dysfunction (e.g., a spouse with whom there is substantial conflict).

Advances in regenerative medicine aim to restore erectile tissue.
Stem cell therapy is being researched for ED.
Platelet-rich plasma (PRP) injections are experimental.
These treatments target tissue repair and blood vessel growth.
Are still in early clinical trial phases.
Consult specialists to explore emerging options.

Group or individual cognitive behavior therapy; psychosexual therapy, including sensate focus technique; and therapy aimed at improving relationship difficulties may help to improve sexual dysfunction in men. A 2007 Cochrane review found that men who received group therapy plus sildenafil had more successful intercourse and were less likely to drop out of the study compared with those who received only sildenafil.36 When comparing psychosocial interventions versus alprostadil injections and vacuum pump devices, no differences in effectiveness were found.36 In some cases, education about medical and psychosocial etiologies of ED in conjunction with physician reassurance may prove adequate to restore normal male sexual function. Men with ED should be considered for cardiovascular risk screening.15 ED rates differ significantly in patients with established coronary artery disease (CAD). On average, ED symptoms present three years earlier than CAD symptoms.37 Men with ED have a 75 percent increased risk of peripheral vascular disease.38 The Prostate Cancer Prevention Trial determined that men with ED have a significantly greater likelihood of having angina, myocardial infarction, stroke, transient ischemic attack, congestive heart failure, or cardiac arrhythmia compared with men without ED.39 Because most men are asymptomatic before an acute coronary syndrome, ED may serve as a sentinel marker for prompting discussions centered on promotion of cardiovascular risk stratification and modification.

What is the treatment for ED?

The truth is that ED has various underlying causes, and those who are confronting it face varying challenges in treatment due to other potential health conditions.

Cialis (tadalafil (cialis))

First-line therapy for ED is aimed at lifestyle changes and modifying pharmacotherapy that may contribute to ED8 (Table 26). Sedentary lifestyle, a significant risk factor for cardiovascular disease, may also be a modifiable risk factor for ED.15 Obesity nearly doubles the risk of ED3; one study determined that one third of men who were obese improved their ED with moderate weight loss and an increase in the amount and duration of regular exercise.14 The risk of moderate or total ED is almost double in men who smoke compared with nonsmokers.16 Patient education should be aimed at increasing exercise, losing weight to achieve a body mass index (BMI) less than 30 kg per m2, and stopping smoking. Phosphodiesterase type 5 (PDE5) inhibitors are the most effective oral drugs in the treatment of ED,9,12 and should be considered first-line therapy.8,14,17 Retail sales of sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra) approached $1.48 billion in 2007.18 Sildenafil has been found to be effective and safe in cases of ED associated with diabetes mellitus17,19 and spinal cord injury,20 and in men with sexual dysfunction secondary to antidepressant therapy.21 Compared with placebo, sildenafil has been shown to improve erections (74 versus 21 percent; number needed to treat [NNT] = 2)22 and results in more frequent intercourse attempts (57 versus 21 percent; NNT = 3).23 Approximately one third of men with ED do not respond to therapy with PDE5 inhibitors. These agents are not effective for improving libido.24 The three PDE5 inhibitors are considered to be relatively similar in effectiveness, but there are differences in dosing, onset of action, and duration of therapeutic effect (Table 6).25 There are no rigorous data to suggest that one PDE5 inhibitor is superior to another. An open-label trial found that patients preferred tadalafil and vardenafil over sildenafil,26 yet most evidence supports equal effectiveness between sildenafil and vardenafil.27 PDE5 inhibitors are generally well tolerated, with mild transient adverse effects of headache, flushing, dyspepsia, rhinitis, and abnormal vision.

For You

Headache is the most commonly reported adverse effect, occurring in approximately 10 percent of patients. Rare but important adverse effects include dizziness, syncope, and nonarteritic anterior optic neuropathy (predominantly from crossover phosphodiesterase type 6 inhibition). PDE5 inhibitors should not be taken concomitantly with nitrates because this may lead to a synergistic effect, resulting in a potentially serious, even fatal, decrease in blood pressure. PDE5 inhibitors are metabolized by the cytochrome P450 3A4 and may affect metabolism of protease inhibitors and antifungal medications. Intracavernosal pressure and PDE5 activity are androgen-dependent.

Research Needs and Future Directions

The prevalence of hypogonadism (defined as a morning serum total testosterone level less than 300 ng per dL [10.41 nmol per L]) in men with ED is estimated to be 5 to 10 percent.13,28 In men with hypogonadism, testosterone supplementation is superior to placebo in improving erections and sexual function. Response rates are higher in primary versus secondary testicular failure, and with transdermal versus oral or intramuscular testosterone.13 Supplementation is also associated with improved satisfaction with erectile function and sexual desire.29 Men with hypogonadism who failed a trial of sildenafil were found to have significant improvement in erectile function with the addition of testosterone supplementation.30 Testosterone supplementation may result in erythrocytosis, elevated serum trans-aminase levels, exacerbation of untreated sleep apnea, benign prostatic hyperplasia, and an increased risk of adenocarcinoma of the prostate. Men receiving testosterone supplementation require more frequent monitoring of hemoglobin, serum transaminase, and prostate-specific antigen levels, and prostate examinations.31 Alprostadil (Caverject) is a viable second-line therapeutic option for the treatment of ED. It should initially be administered in the physician's office at the lowest dose and sequentially titrated to an adequate erectile response while monitoring for syncope. The physicians should also provide education on self-administration.8 Intra-cavernosal alprostadil is more effective, better tolerated, and preferred by men over the intraurethral form.32 Common adverse effects of intraurethral alprostadil include local penile pain, urethral bleeding, dizziness, and dysuria. So, the question is: What is best erection pills the best treatment for you?

Regular check-ups help monitor underlying health issues causing ED.
Conditions like diabetes and hypertension impact erectile function.
Early diagnosis improves treatment outcomes.
Medication adjustments may be necessary over time.
Open communication with a healthcare provider is key.
Proactive health management can prevent worsening of ED.

Aside from underlying health considerations, everything from price to how you take a medication can affect your decision. But we're here to demystify ED and your treatment options. To help you out, we’ve reviewed the major online providers and treatments and analyzed a large swath of relevant scientific research. In this guide, we’ll break down all of your best options. First, to orient you to this landscape, here is a roadmap that breaks down the diverse treatment paths you might take and our characterization of their merits.

Vacuum erection devices create a vacuum to draw blood into the penis.
They use a constriction ring to maintain the erection.
Non-drug treatment options are effective for some men.
Proper use is important for safety and effectiveness.
They are drug-free, non-invasive alternatives.
Can be used with other ED treatments.

Most likely to help: Prescription PDE5i medication like sildenafil (Viagra), tadalafil (Cialis), etc. Next most likely to help: Mental health care Best in-office treatment alternative to prescription: Shockwave therapy Best OTC budget options to try: ED rings and/or certain supplements And now, for those in a hurry, here’s a quick snapshot of our specific recommendations across that roadmap.

Managing Expectations: Onset of Action and Sexual Planning